Trends in receiving chemotherapy for advanced cancer patients at the end of life by �씠�씗�듅 et al.
Lee et al. BMC Palliative Care  (2015) 14:4 
DOI 10.1186/s12904-015-0001-7RESEARCH ARTICLE Open AccessTrends in receiving chemotherapy for advanced
cancer patients at the end of life
Hee Seung Lee, Kyeong Hyeon Chun, Dochang Moon, Hahn Kyu yeon, Sanghoon Lee and SooHyeon Lee*Abstract
Background: The use of chemotherapy in advanced cancer patients has increased with the development of
novel, high-efficacy anticancer therapeutic agents. In the current study, we analyzed the 10-year trends in patients
receiving chemotherapy at the end of life.
Method: We retrospectively reviewed mortality data for advanced cancer patients who died in 2000, 2005, and
2010 at a single institution. The trends of receiving palliative chemotherapy at the end of life were assessed for
each year. In addition, logistic regression analysis was performed to determine the factors associated with receiving
chemotherapy.
Results: We analyzed the records of 2,345 patients who died of cancer. Patients with less responsive tumors
were less likely to receive chemotherapy than patients with responsive tumors at the time of death. Patients who
were ≥ 65 years were less likely to receive chemotherapy compared with patients who were < 65 years at the end
of life. However, the proportion of older patients receiving chemotherapy in the last month of life increased in 2010
(44.2%) compared with 2005 (32.7%) and 2000 (25.7%). Compared with the year 2000, the likelihood of receiving
chemotherapy during the last 1 month of life increased in 2005 (odds ratio [OR], 2.05; 95% confidence interval [CI],
1.60–2.62) and 2010 (OR, 4.42; 95% CI, 3.51–5.57).
Conclusions: The proportion of patients receiving chemotherapy at the end of life increased successively from
2000 to 2005 to 2010. Physicians should consider whether to continue chemotherapy at the end of life.
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Novel, high efficacy anticancer therapeutic agents have
been developed in the last decade [1-6]. The availability
of new anticancer agents has prolonged the timeline of
chemotherapy use in cancer patients [1]. In particular,
the use of chemotherapy at the end of life (EOL) in ad-
vanced cancer patients has increased [7], and EOL care
has become increasingly aggressive [8]. In a study by Liu
et al. [7], the rates of continued chemotherapy during
the last month of life increased from 17.5% in 2001 to
21.0% in 2006. Previous studies also demonstrated that
the proportion of indicators for aggressive EOL care,
including receiving EOL chemotherapy, increased sig-
nificantly in the last 10 years [6]. Many advanced cancer* Correspondence: socmed0127@gmail.com
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unless otherwise stated.patients receive EOL chemotherapy, even those with
cancer types known to be unresponsive to chemotherapy
[9]. However, in some studies, patients who received pal-
liative chemotherapy during the last month of life had a
significantly shorter survival time from the beginning of
palliative treatment to death and more frequent hospital
admissions [6,10,11].
Recognition of the importance of high quality EOL
care has continued to increase. However, few studies
have included recent data and the use of oral chemo-
therapeutic agents. Therefore, we evaluated the trends in
EOL chemotherapy in advanced cancer patients who
died between 2000 and 2010 in a single institution in the
Republic of Korea to confirm recent trends in receiving
EOL chemotherapy.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study population
We analyzed the trends in receiving EOL chemotherapy
during a recent 10-year period at Severance Hospital, a
tertiary referral hospital in the Republic of Korea that
does not have an inpatient hospice unit. We retrospect-
ively reviewed the records of advanced cancer patients
who died at Severance Hospital in 2000, 2005, or 2010
to determine the number of patients who received
chemotherapy for 6, 3, and 1 month before death. The
exclusion criteria were as follows: 1) < 18 or > 90 years
old (n = 65), 2) uncertainty regarding the time and regi-
men of the last chemotherapy (n = 20), and 3) died in a
location other than Severance Hospital (n = 80). The
study protocol conformed to the ethical guidelines of
the 1975 Declaration of Helsinki. The protocol of this
study was approved by the institutional review board
(4-2014-1054) at Severance Hospital and written in-
formed consent for this study was not required by the
institutional review board because the researchers only
accessed the database for analysis purposes and per-
sonal information was not used.
Patient information was collected from electronic
medical records, including age, gender, date of diagnosis,
marital status, place of residence, job, date of death, and
type of cancer. The patients were divided into groups
according to age (younger vs. older than 65 years) and
place of residence based on a previous study [12].
Patients were also grouped by type of cancer, because
some studies suggested that selectivity in the EOL
chemotherapy regimen was based on the responsive-
ness of the cancer type. Specifically, breast, stomach,
lung, ovarian, and colon cancers tend to be more
responsive to chemotherapy, whereas melanoma, gall-
bladder, pancreatic, and hepatocellular cancer tend to
be less responsive to chemotherapy [9,13-16]. Finally,
the type of chemotherapy was characterized according
to intravenous or oral administration.
Statistical analyses
Chi-squared tests were performed to evaluate potential
differences in patients who received versus did not
receive chemotherapy in each of the years evaluated.
Univariate logistic regression analyses were performed to
evaluate whether each factor affected the number of
individuals who received EOL chemotherapy in each
month prior to death. Then, multivariate logistic regres-
sion analyses were performed after adjusting for factors
that were significant in the univariate regression analysis
to identify the factors related to the number of patients
receiving EOL chemotherapy in each month prior to
death. Data were analyzed using SPSS version 20.0
(SPSS, Chicago, IL, USA), and P < 0.05 was considered
to be statistically significant.Results
Patient characteristics
A total of 2,510 patients were eligible for inclusion in
the current study. The final analysis included 2,345
patients who died at Severance Hospital in 2000, 2005,
or 2010, with 601, 702, and 1,042 deaths in each respect-
ive year. The 601 patients who died in 2000 included
393 (65%) males and 208 (35%) females, with a median
age of 58 (range, 18–89) years. The records of the 702
patients who died in 2005 included 440 (62%) males and
262 (38%) females, with a median age of 61 years (range
18–88). Finally, the 1042 patients who died in 2010
included 685 (65%) males and 357 (35%) females, with a
median age of 62 years (range 19–90). No differences
were observed in the gender proportions between 2000
and 2010 (65% males vs. 35% females). The use of
chemotherapy at the EOL was significantly associated
with younger age, the chemosensitivity of the cancer
type, and the use of oral chemotherapeutic agents. The
use of chemotherapy at the EOL was higher in males,
but not significantly. Table 1 shows the baseline charac-
teristics of the advanced cancer patients who received
EOL chemotherapy.
Proportion of patients receiving EOL chemotherapy
More than half of the patients in 2010 received EOL
chemotherapy, and the use of EOL chemotherapy in-
creased in each year evaluated (Figure 1). The proportion
of patients receiving chemotherapy during the last month
of life increased from 22% in 2000 to 56% in 2010. The
percentage of patients receiving chemotherapy during the
last 6 months of life increased from 33% in 2000 to 57% in
2010 (P < 0.001). In addition, the number of patients who
received oral chemotherapeutic agents increased between
2000 and 2010 (Figure 2).
Univariate analyses revealed that age was significantly
associated with receiving EOL chemotherapy. Patients <
65 years were more likely to receive chemotherapy dur-
ing the last 6, 3, and 1 month of life compared with
older patients (P < 0.001). The proportion of patients
aged ≥ 65 years receiving chemotherapy in the last
month of life was 44.2% in 2010, compared with 32.7%
in 2005 and 25.7% in 2000. Patients with cancers that
were relatively chemo-sensitive were more likely to
receive chemotherapy during the last month of life in 2000
and 2005 compared with those with chemo-insensitive
cancers (P = 0.045 and P < 0.001, respectively). The pro-
portion of patients who received oral chemotherapeutic
agents at the EOL increased in 2010 (P < 0.001).
Table 2 shows the OR of receiving chemotherapy
according to the year of death using multivariate ana-
lysis. Compared with patients receiving chemotherapy in
2000, those in 2005 and 2010 were more likely to receive
chemotherapy during the last 6, 3 or 1 month of life
Table 1 Characteristics of the cancer patients who received or who did not receive chemotherapy during the last months of life
Year of death 2000 2005 2010
Months
before death
6 months 3 months 1 month 6 months 3 months 1 month 6 months 3 months 1 month
Number CTx (+) P value CTx (+) P value CTx (+) P value CTx (+) P value CTx (+) P value CTx (+) P value CTx (+) P value CTx (+) P value CTx (+) P value
201 (33) 152 (25) 136 (22) 325 (46) 283 (40) 260 (37) 597 (57) 497 (47) 582 (56)
Gender
Male 132 (65.7) NS 98 (64.5) NS 83 (61.0) NS 199 (61.2) NS 199 (61.2) NS 165 (63.5) NS 371 (62.1) 0.005 314 (3.2) NS 383(65.8) NS
Female 69 (34.3) 54 (35.5) 53 (39.0) 126 (38.8) 126 (38.8) 95 (36.5) 226 (37.9) 183 (36.8) 199 (34.2)
Age
≥65 years 31 (15.4) <0.001 29 (19.1) 0.002 35 (25.7) 0.005 83 (25.5) <0.001 83 (25.5) <0.001 85 (32.7) <0.001 232 (38.9) <0.001 197 (39.6) 0.004 257 (44.2) NS
<65 years 170 (84.6) 123 (80.9) 101 (74.3) 242 (74.5) 242 (74.5) 175 (67.3) 365 (61.1) 300 (60.4) 325 (55.8)
Place of residence
City 144 (71.6) NS 111 (73.0) NS 87 (64.0) NS 241 (74.2) NS 241 (74.2) NS 194 (74.6) NS 412 (69.0) NS 351 (70.6) NS 410 (70.4) NS
Other 57 (28.4) 41 (27.0) 49 (36.0) 84 (25.8) 84 (25.8) 66 (25.4) 185 (31) 146 (29.4) 172 (29.6)
Chemosensitivity
Others 51 (25.4) NS 44 (28.9) NS 53 (39.0) 0.045 86 (26.5) 0.006 86 (26.5) 0.006 99 (38.1) <0.001 178 (29.8) 0.01 149 (30.0) 0.003 192 (33.0) 0.002
Sensitive 82 (40.8) 63 (41.4) 42 (30.9) 166 (51.1) 166 (51.1) 116 (44.6) 299 (50.1) 255 (51.3) 268 (46.0)
Insensitive 68 (33.8) 45 (29.6) 41 (30.1) 73 (22.5) 73 (22.5) 45 (17.3) 120 (20.1) 93 (18.7) 122 (21.0)
Chemotherapy
Oral CTx 10 (5.0) <0.001 14 (9.2) <0.001 17 (12.5) <0.001 20 (6.2) <0.001 20 (6.2) <0.001 26 (10) <0.001 138 (23.1) <0.001 125 (25.2) <0.001 89 (15.3) <0.001
IV CTx 191 (95.0) 138 (90.8) 119 (87.5) 305 (93.8) 305 (93.8) 234 (90) 459 (76.9) 372 (74.8) 493 (84.7)
Variables are expressed as n (%).
NS, not significant.
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Figure 1 The proportion of patients receiving chemotherapy at the end of life in 2000, 2005, and 2010.
Lee et al. BMC Palliative Care  (2015) 14:4 Page 4 of 6(P < 0.001). The OR for receiving chemotherapy in the
last month of life was 2.05 (95% CI, 1.60–2.62) in 2005
and 4.42 (95% CI, 3.51–5.57) in 2010 compared with
2000. The difference in OR between 2010 and 2000
was greater for receiving chemotherapy during the last
month of life compared with the last 6 months of life.
Discussion
Physicians are increasingly considering the importance
of patient quality of life at the EOL. In patients with
advanced cancer, anticancer treatments aim to improve
the quality of life and overall survival. The current study
revealed serial changes in EOL chemotherapy. Nappa
et al. found no differences in age, gender, or chemothera-
peutic agent among patients who did or did not receive
chemotherapy within 1 month of death. However, other
studies found differences in age, cancer type, cancer
chemo-sensitivity, and gender in patients who received
chemotherapy at the EOL [12,16-18]. The current study
revealed a significant association between EOL chemo-
therapy and age, gender, cancer chemo-sensitivity, and use
of oral chemotherapeutic agents. Males were more likely
to receive chemotherapy at the EOL than were females.
Consistent with this, a previous study reported that males5
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Figure 2 The proportion of patients receiving oral chemotherapeutichad a stronger preference for life-sustaining treatment
compared with females [19]. Cancer chemo-sensitivity
was also a significant factor for the administration of
chemotherapy at the EOL, although it was less important
recently after the introduction of targeted therapeutic
agents. In addition, older patients received EOL chemother-
apy less frequently than did younger patients. However,
patients older than 65 years have received chemotherapy
increasingly as survival times increases.
The overall rates of chemotherapy given within 1 month
of death were similar between the current and previous
studies. Previous studies reported rates of chemotherapy
within 1 month of death in advanced cancer patients of
18–43% [1,10,12,20]. Yun et al. found that chemotherapy
was given to 48.7% of patients in the last 6 months, 43.9%
in the last 3 months, and 30.9% in the last month of life
[12]. The current study found that a high proportion of
cancer patients received chemotherapy in the last
month of life, and that this proportion increased over a
recent 10-year period. Several reasons might explain
the increasing use of EOL chemotherapy. First, various
novel chemotherapeutic agents have been developed
recently, including oral chemotherapeutic agents. This
has increased the opportunity for advanced cancer12
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15
1month
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2005
2010
agents in 2000, 2005, and 2010.
Table 2 Odds ratios of receiving chemotherapy in 2005 and 2010 compared with 2000
6 months 3 months 2 months 1 month
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
2000 Ref Ref Ref Ref
2005 1.94 (1.53–2.43) 2.17 (1.70–2.77) 1.97 (1.54–2.51) 2.05 (1.60–2.62)
2010 3.26 (2.61–4.06) 3.08 (2.45–3.87) 3.50 (2.79–4.39) 4.42 (3.51–5.57)
P for trend <0.001 <0.001 <0.001 <0.001
OR, odds ratio; CI, confidence interval.
Adjusted for age, gender, chemosensitivity, and route of administration.
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insurance system was changed in Korea in 2009, which
decreased the financial burden for advanced cancer
patients. Before these changes, the national health
insurance system covered 80% of the total medical fee;
however, since 2009 it has covered 95% of the total
medical fees. This systemic change might have also
affected the trends toward receiving EOL chemotherapy.
In addition, attitudes toward EOL treatment are different
culturally between Korea and Western countries [21,22].
In Korea, there is a cultural trend of continuing palliative
chemotherapy at the EOL rather than receiving hospice
care. The hospice system is also not well-developed or
established in Korea.
Aggressive cancer care is not necessarily wrong for
patients at the EOL. For example, such care might fit
with the preferences of advanced cancer patients who
want to continue potentially life-prolonging treatment.
However, previous studies showed that aggressive pallia-
tive chemotherapy at the EOL decreases the quality of
life and can increase mortality. Similarly, Keam et al.
found shorter survival times and more frequent hospital
admissions among patients who received chemotherapy
at the EOL [11]. Overly aggressive EOL chemotherapy is
recognized as poor quality cancer care [23,24]. Previous
studies also showed that ceasing aggressive cancer
treatment earlier and introducing palliative care might
increase the survival time and quality of life of advanced
cancer patients [25]. Therefore, physicians should consider
the risks and benefits of continuing palliative chemother-
apy at the EOL to allow patients to die with dignity.
The present study has several unique strengths com-
pared with previous studies. First, to our knowledge, this
is the largest series to assess EOL chemotherapy in
advanced cancer patients. Although one previous study
analyzed a large number of patients between 2001 and
2006 [7], the current study evaluated a longer period
(from 2000 to 2010) and divided EOL into three lengths
of time. The identification of serial changes according to
years and the last months before death has increased
our understanding of the trends in receiving chemother-
apy at the EOL. Second, in contrast to previous reports
the current study included patients who received oralchemotherapeutic agents, because these novel targeted
agents are now available and are convenient for elderly
patients. Finally, we analyzed the effect of the health
insurance system on the prevalence of receiving chemo-
therapy in the Republic of Korea.
Nevertheless, this study has some limitations. The data
might have been overestimated because we did not
include patients who died at locations other than the
hospital who potentially did not select for chemotherapy
or were discharged for supportive care. In addition, direct
comparisons with earlier studies are difficult, because the
current study was performed at a single tertiary hospital.
In addition, care at teaching hospitals is likely to be more
aggressive [24]. Nevertheless, these data confirm recent
treatment trends in advanced cancer patients, because
most advanced cancer patients tend to visit large-volume
hospitals after cancer diagnosis. Finally, we considered
only the proportion of patients who received chemother-
apy as an indicator of aggressive treatment. Various factors
related to aggressive treatment affect EOL care in patients
with advanced cancer. Despite these limitations, the
results of the current study are informative. There have
been few previous reports related to palliative care using
chemotherapy and the use of oral chemotherapeutic
agents in patients at the EOL.Conclusion
The proportion of patients receiving chemotherapy at the
EOL increased from 2000 to 2005 to 2010. Although the
data could have been overestimated, physicians should
consider whether to continue chemotherapy at the EOL.
In a future study, we will review other information includ-
ing ER visits, hospital admission, ICU admission, and
medical costs to evaluate treatment aggressiveness.Competing interests
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